The North America Oral Antiviral Market should witness market growth of 1.7% CAGR during the forecast period (2023-2029).
There is a market opportunity for oral antiviral products due to expansion and innovation in the pharmaceutical sector. Increased product approvals for various these medicines and an increase in the number of new medication studies conducted by major manufacturers are expected to benefit market growth. In addition, the demand for efficient oral antiviral medications is also increasing due to the growing incidence of viral infections, including hepatitis and influenza, propelling the market's expansion.
Due to the accessibility of enhanced healthcare infrastructure, a surge in unmet healthcare needs, a boost in the prevalence of adult cases of the human immunodeficiency virus (HIV), and an increase in the need for these medications for the treatment of viral infection, emerging markets are predicted to drive the growth of the market. Additionally, the demand for better healthcare services is growing, the government is making sizable expenditures to upgrade the healthcare infrastructure, and the medical tourism sector is expanding rapidly in emerging nations. These factors contribute to the rapid growth of the healthcare sector in these economies.
The pharmaceutical sector in Mexico is regarded as one of the biggest in the world. Patented drugs comprise 51% of the market in Mexico's pharmaceutical industry by value, followed by generic drugs with 35% of the market and over-the-counter products for the remaining 14%. The growth of biosimilars, whose sales are anticipated to rise in the future years, is one factor driving Mexico's pharmaceutical industry. With the release of updated medication guidelines, regional R&D and biosimilar industry manufacturing has substantially improved, and numerous companies have announced the introduction of novel products and investments. As a result, the region's development of oral antiviral pharmaceuticals is anticipated to boost market expansion, along with expanding drug imports and exports and a robust pharmaceutical sector.
The US market dominated the North America Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $11,996.1 million by 2029. The Canada market is registering a CAGR of 4.1% during (2023-2029). Additionally, The Mexico market would showcase a CAGR of 3.1% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
There is a market opportunity for oral antiviral products due to expansion and innovation in the pharmaceutical sector. Increased product approvals for various these medicines and an increase in the number of new medication studies conducted by major manufacturers are expected to benefit market growth. In addition, the demand for efficient oral antiviral medications is also increasing due to the growing incidence of viral infections, including hepatitis and influenza, propelling the market's expansion.
Due to the accessibility of enhanced healthcare infrastructure, a surge in unmet healthcare needs, a boost in the prevalence of adult cases of the human immunodeficiency virus (HIV), and an increase in the need for these medications for the treatment of viral infection, emerging markets are predicted to drive the growth of the market. Additionally, the demand for better healthcare services is growing, the government is making sizable expenditures to upgrade the healthcare infrastructure, and the medical tourism sector is expanding rapidly in emerging nations. These factors contribute to the rapid growth of the healthcare sector in these economies.
The pharmaceutical sector in Mexico is regarded as one of the biggest in the world. Patented drugs comprise 51% of the market in Mexico's pharmaceutical industry by value, followed by generic drugs with 35% of the market and over-the-counter products for the remaining 14%. The growth of biosimilars, whose sales are anticipated to rise in the future years, is one factor driving Mexico's pharmaceutical industry. With the release of updated medication guidelines, regional R&D and biosimilar industry manufacturing has substantially improved, and numerous companies have announced the introduction of novel products and investments. As a result, the region's development of oral antiviral pharmaceuticals is anticipated to boost market expansion, along with expanding drug imports and exports and a robust pharmaceutical sector.
The US market dominated the North America Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $11,996.1 million by 2029. The Canada market is registering a CAGR of 4.1% during (2023-2029). Additionally, The Mexico market would showcase a CAGR of 3.1% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
Scope of the Study
By Indication
- Human Immunodeficiency Virus (HIV)
- Hepatitis
- Influenza
- Others
By Drug Class
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Oral Antiviral Market by Indication
Chapter 4. North America Oral Antiviral Market by Drug Class
Chapter 5. North America Oral Antiviral Market by Distribution Channel
Chapter 6. North America Oral Antiviral Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
